200 related articles for article (PubMed ID: 12975380)
1. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk.
Fakruddin JM; Laurence J
J Biol Chem; 2003 Nov; 278(48):48251-8. PubMed ID: 12975380
[TBL] [Abstract][Full Text] [Related]
2. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling.
Wang MW; Wei S; Faccio R; Takeshita S; Tebas P; Powderly WG; Teitelbaum SL; Ross FP
J Clin Invest; 2004 Jul; 114(2):206-13. PubMed ID: 15254587
[TBL] [Abstract][Full Text] [Related]
3. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
Takayanagi H; Ogasawara K; Hida S; Chiba T; Murata S; Sato K; Takaoka A; Yokochi T; Oda H; Tanaka K; Nakamura K; Taniguchi T
Nature; 2000 Nov; 408(6812):600-5. PubMed ID: 11117749
[TBL] [Abstract][Full Text] [Related]
4. Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis.
Fakruddin JM; Laurence J
Clin Exp Immunol; 2004 Sep; 137(3):538-45. PubMed ID: 15320903
[TBL] [Abstract][Full Text] [Related]
5. WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss.
Modarresi R; Xiang Z; Yin M; Laurence J
Am J Pathol; 2009 Jan; 174(1):123-35. PubMed ID: 19095956
[TBL] [Abstract][Full Text] [Related]
6. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
7. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis and bone resorption.
Zheng H; Yu X; Collin-Osdoby P; Osdoby P
J Biol Chem; 2006 Jun; 281(23):15809-20. PubMed ID: 16613848
[TBL] [Abstract][Full Text] [Related]
8. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
9. Signaling crosstalk between RANKL and interferons in osteoclast differentiation.
Takayanagi H; Kim S; Taniguchi T
Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S227-32. PubMed ID: 12110142
[TBL] [Abstract][Full Text] [Related]
10. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
11. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation.
Hayashi T; Kaneda T; Toyama Y; Kumegawa M; Hakeda Y
J Biol Chem; 2002 Aug; 277(31):27880-6. PubMed ID: 12023971
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function.
Zavrski I; Krebbel H; Wildemann B; Heider U; Kaiser M; Possinger K; Sezer O
Biochem Biophys Res Commun; 2005 Jul; 333(1):200-5. PubMed ID: 15936724
[TBL] [Abstract][Full Text] [Related]
13. Monokine induced by interferon-gamma is induced by receptor activator of nuclear factor kappa B ligand and is involved in osteoclast adhesion and migration.
Kwak HB; Lee SW; Jin HM; Ha H; Lee SH; Takeshita S; Tanaka S; Kim HM; Kim HH; Lee ZH
Blood; 2005 Apr; 105(7):2963-9. PubMed ID: 15585657
[TBL] [Abstract][Full Text] [Related]
14. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
15. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Zhang Z; Jimi E; Bothwell AL
J Immunol; 2003 Oct; 171(7):3620-6. PubMed ID: 14500659
[TBL] [Abstract][Full Text] [Related]
16. Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
Jain RG; Lenhard JM
J Biol Chem; 2002 May; 277(22):19247-50. PubMed ID: 11937496
[TBL] [Abstract][Full Text] [Related]
17. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
18. Association of sustained ERK activity with integrin beta3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiation.
Kim HH; Chung WJ; Lee SW; Chung PJ; You JW; Kwon HJ; Tanaka S; Lee ZH
Exp Cell Res; 2003 Oct; 289(2):368-77. PubMed ID: 14499638
[TBL] [Abstract][Full Text] [Related]
19. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
